Last updated: 2026-09-28 13:37:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
SCYNEXIS, Inc. (SCYX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.63, with a market capitalisation of $43.68M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.53 to $9.12. This page covers its latest market performance, valuation, price trends and company information.
$43.68M | |
$4.41 | |
$1,200.00 | |
$3.53 | |
$4.39 | |
5.21M | |
134.34K | |
-- | |
$9.12 | |
$3.53 | |
-- | |
-- |
SCYNEXIS, Inc. (SCYX) is currently trading at $4.63 as of 2026-09-28 13:34:00, up 5.44% ($0.24) from the previous close of $4.39
During today's regular trading session, SCYX has traded between $3.53 and $1,200.00, with a trading volume of 5.21M shares. The current price is near the lower end of today's range.
Over the past seven days, SCYNEXIS, Inc. (SCYX) moved from $4.45 to $4.63, representing a gain of 4.02% ($0.18).
The stock traded between $4.11 and $6.30 during the period. The latest price is near the lower end of the 7-day range, indicating moderate upward.
The average daily volume was 69.85 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 19.7%
SCYX is currently trading at $4.63, placing it 19.7% of the way from its 52-week low of $3.53 to its 52-week high of $9.12. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 29 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of SCYNEXIS, Inc. (SCYX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.